Bausch + Lomb's Q1 2026 10-Q showed the Pharmaceuticals segment swing from 4% to 22% operating margin — a $55M profit jump in one quarter. The headline is mechanical: XIIDRA inventory step-up amortization rolled off ($22M Q1 2025 drag), enVista IOL recall lapped, post-launch promo spend declined. What's unusual is what BHC's CFO said on the same-day Q1 2026 call about when BHC will sell BLCO.

What the filing shows

Revenue $1,244M, +9.4% reported / +5.7% constant currency. Operating income swung -$83M → +$33M. Pharma segment profit $66M (22% margin) on $305M revenue, up from $11M (4%). Vision Care +5% CC, Surgical +1% CC. Cash $268M (down from $383M); $32M operating cash flow swallowed by $100M capex and a $35M MIEBO milestone payment (Novaliq annual sales threshold hit). Debt $5.1B at 7.43% blended; $1.4B October 2028 Secured Notes at 8.375% remain the wall. BHC owns 87%.

On BHC's Q1 call, CFO JJ Charhon explicitly linked Xifaxan exclusivity to BLCO timing: if BHC loses Xifaxan (Teva final FDA approval received; D.C. Circuit appeal pending), BHC needs BLCO assets earlier than originally planned. The BLCO separation gating constraint shifted from internal (BHC leverage progression) to external (a court ruling).

What the market shows

+40% YoY, RSI 36, idio variance 28%. Eye health cohort is split: ALC -33% YoY (RSI 15) and COO -25% (RSI 14) are deeply oversold; specialty ophthalmic (HROW +59%, EYPT +121%, TARS +31%) is outperforming. ALC announced a $1.5B buyback the same week. COO disclosed "engaged advisers" on strategic alternatives in March.

Options are pricing a summer catalyst. IV Rank 295%, P/C ratio 0.04 (calls 25× puts), call IV 35pp above puts. Heavy positioning at $13 ITM calls and $18-20 OTM speculation. The 105-day Aug 21 expiration covers Q2 earnings; the 224-day Dec expiration has only 32 OI.

EV/EBITDA scenarios probability-weighted (0.40 bhc_loses / 0.30 bhc_wins / 0.25 mixed / 0.05 delayed) give a target roughly flat to current. Backing out the market's implied probability gives ≈46% bhc_loses vs our 40%. The +40% YoY rally has front-run the catalyst.

Why the gap exists

Pharma growth is sectoral; pharma margin inflection is idio; consensus blends them. The discriminator (BLCO +12pt vs ALC +0.4pt at matched +6% CC growth) requires cross-reading two filings the same week. BHC's CFO buried the BLCO timing linkage in a same-day transcript few BLCO-only readers parse. The cohort split (megacap RSI 13-15 vs specialty +30-120% YoY) is visible but lacks a published synthesis.

Risks

Court ruling timing and direction we cannot handicap. BLCO idio variance is 28% — outright long is 72% factor noise (closet indexer to specialty pharma + eye health cohort). ALC mean reversion: a $1.5B buyback authorized at RSI 15 supports the stock near-term and complicates any pair short leg. The $1.4B 2028 debt wall at 8.375% requires resolution within ≈2.5 years.

Catalysts

BLCO Q2 2026 10-Q (~early August) tests pharma margin sustainability. D.C. Circuit Xifaxan ruling (estimated 2026-2027 window) collapses the scenario tree. BHC advisor hire 8-K — currently absent (separation costs $1M Q1). Mexico facility tariff arbitrage disclosure: $67M goodwill on $8M tangible could be a 0% MFN/USMCA play, currently unquantified.

What would change our mind

Q2 2026 pharma margin <15% — inflection thesis fundamentally damaged. BHC retains Xifaxan via successful appeal — separation pushed indefinitely; BLCO trades on standalone fundamentals, multiple compresses. ALC RSI ≥30 reaches before BLCO catalyst — pair window closes. COO transaction disclosed first — eye health M&A demand confirmed but BLCO isn't the vehicle.

Evidence